Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $650,500.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $26.02, for a total value of $650,500.00. Following the transaction, the director owned 882,911 shares in the company, valued at approximately $22,973,344.22. The trade was a 2.75% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

CeriBell Stock Performance

NASDAQ CBLL opened at $25.75 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.79 and a current ratio of 8.18. The stock’s fifty day moving average is $25.66 and its two-hundred day moving average is $21.15. The firm has a market capitalization of $1.00 billion, a P/E ratio of -13.27 and a beta of 0.86. CeriBell, Inc. has a fifty-two week low of $13.52 and a fifty-two week high of $28.89.

CeriBell (NASDAQ:CBLL – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The company had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. On average, research analysts anticipate that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its holdings in CeriBell by 25.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 350,570 shares of the company’s stock valued at $8,550,000 after buying an additional 70,261 shares during the period. Entropy Technologies LP acquired a new position in CeriBell in the third quarter valued at about $803,000. Jump Financial LLC lifted its position in CeriBell by 153.2% in the third quarter. Jump Financial LLC now owns 93,705 shares of the company’s stock valued at $2,285,000 after buying an additional 56,702 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in CeriBell during the third quarter worth about $4,466,000. Finally, Squarepoint Ops LLC purchased a new position in CeriBell during the second quarter worth about $638,000.

Wall Street Analyst Weigh In

CBLL has been the subject of several recent analyst reports. TD Cowen raised their price objective on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Canaccord Genuity Group increased their price target on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.

Check Out Our Latest Analysis on CBLL

About CeriBell

(Get Free Report)

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

Read More

Insider Buying and Selling by Quarter for CeriBell (NASDAQ:CBLL)

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.